For the third time in 2024, UPMC Enterprises is celebrating a successful exit from its portfolio as Realyze Intelligence has been acquired by Carta Healthcare.
The acquisition of Realyze, an AI platform for clinical trials that was incubated at Enterprises before being spun-out in 2020, demonstrates the strength of UPMC Enterprises. We identify challenges in health care and work with clinical and technical experts at UPMC to develop solutions and launch companies that bring value to the broader health care ecosystem.
Realyze co-founders Aaron Brauser and Gilan El Saadawi were Executives in Residence at UPMC Enterprises before launching the company; Brauser became Realyze CEO and Saadawi became Chief Medical Officer.
Carta is acquiring Realyze for its strategic capabilities in oncology, automating the abstraction of data, and workflow for clinical trial matching. The Realyze solution leverages AI to match patients to clinical trials which accelerates research and reduces costs while providing patients with the latest advances in care.
The solution rapidly analyzes structured and unstructured data in electronic health records (EHRs) to identify ideal patients for clinical trials and other research studies. Realyze’s clinician-trained AI can assemble appropriate cohorts in seconds instead of the typical hours or days the process can consume when performed manually.
“Health systems and pharmaceutical companies invest billions annually to identify and enroll patients for clinical trials — a process that is not only costly but labor-intensive and time-consuming,” Brauser said. “High-quality, timely data is essential for accurately identifying eligible patients, yet much of it remains trapped in EHRs and other systems. We are excited to revolutionize clinical trial matching and reuse the data to enhance research, optimize care pathways, and improve patient outcomes with Carta Healthcare.”
Realyze is utilized by leading cancer centers, including UPMC Hillman Cancer Center, and is part of the Memorial Sloan Kettering Cancer Center Innovation Hub. The CancerX Accelerator Program also selected Realyze as part of its inaugural program earlier this year.
Carta Healthcare’s platform applies AI to structured and unstructured data to decrease the time and costs for data abstraction. The combined technologies’ powerful automation can provide dramatically faster insights and significantly reduced labor demands for clinical data registry abstraction, research, and internal clinical quality performance programs in oncology, cardiovascular health and other specialties.
“We are inspired by Realyze Intelligence’s shared ability to use clinician-trained AI and a human-in-the-loop approach to maximize insights from clinical data, for clinical trials and cancer registries,” said Brent Dover, CEO of Carta Healthcare.
Carta’s platform, enhanced with Realyze’s AI technology, will significantly expand the feasibility of trials and other research while accelerating data abstraction for cancer and other clinical data registries with expert clinician oversight.
Next Steps
- Read about UPMC Enterprises’ accomplishments in 2024 by downloading our Year in Review report.
- Learn more about Carta Healthcare and how it’s combining AI with expert abstractors to turbocharge clinical data abstraction for registries.
